EP-1153 Nasopharyngeal carcinoma treated with intensitymodulated radiotherapy in a non-endemic area  by Letelier, H. et al.
S626                                                                                                                                         3rd ESTRO Forum 2015 
 
66-70 Gy : gross tumor volume + isotropic expansion of 5 mm 
; CTV 59.4-60 Gy: lymph node regions (LNR) at high risk; 
CTV50.4-54 Gy: LNR at low risk. PTV were developed by 
adding to CTV an isotropic expansion of 5 mm. Patients with 
II stage NPC were treated with concurrent CHRT and patient 
with III-IVA/B stage were treated with neoadjuvant CHT 
followed by concurrent CHRT. Acute and late toxicities were 
graded according to Radiation Therapy Oncology 
Group/European Organisation for Research and Treatment of 
Cancer radiation morbidity scoring criteria. 
Results: We retrospectively analyzed 53 patients (pts) with 
pathologically diagnosed NPC, including 37 males and 16 
females; mean age was 52.8 years (range 14-77 years). 
According to the AJCC 2010 staging system 8 pts had II stage, 
30 pts III stage and 15 pts IVA/B stage. At a median follow-up 
of 26 months, 13 pts experienced local regional failure and 
distant metastasis occurred in 11 pts. Reirradiation +/- 
chemotherapy were used as salvage treatment in 6 pts, 
chemotherapy in 2 pts and 2 other pts received surgery (in 1 
pt lymph node dissection and the other pulmonary 
metastasectomy). The 2 years actuarial loco-regional failure–
free survival and disease free survival were 78.9 % and 78.4 
%, respectively. No patients had treatment failure after 24 
months. 
 
 
No grade > 4 acute toxicity and no > 3 late toxicity were 
observed. 
Conclusions: IMRT- SIB combined with concurrent 
chemotherapy +/- neoadjuvant CHT resulted in encouraging 
rates of local regional control with acceptable rates of acute 
and late side effects in patients with locoregionally advanced 
NPC.  
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Purpose/Objective: To evaluate the efficacy and toxicity of 
induction chemotherapy (IC) followed by radiochemotherapy 
(RTCT) versus concurrent radiochemotherapy for 
locoregionally advanced nasopharyngeal cancer (NPC).  
Materials and Methods: Patients with locoregionally 
advanced NPC were treated with three cycles of induction 
chemotherapy (IC) with Taxotere (75 mg/m2) plus cisplatin 
(75 mg/m2), plus 5-Fluoruracil (750 mg/m2) followed by full 
doses of IMRT (70 Gy) concurrently with cisplatin 100 
mg/m(2) every 21 days for three cycles (Group A) or to the 
same RTCT regimen alone (Group B). The outcomes of 
patients was evaluated in terms of overall survival (OS), local 
control (LC), and toxicity. 
Results: From July 2007 until December 2013, 45 patients 
were analyzed. Among them, 23 patients received three 
cycles of IC and 22 patients were treated with concomitant 
radiochemotherapy alone. With a median follow-up of 63 
months for the entire group, (range 3-146), 1-ys, 3-ys and 5-
ys Overall Survival were 79%, 58% and 52% for patients 
treated with induction chemotherapy, and 95%, 89% and 81% 
for RTCT alone, respectively (p=0.04). One-year, 3-ys and 5-
ys Disease Free-Survival were 64%, 41% and 19% for patients 
undergone to IC, 88%, 81% and 65% for patients receiving 
RTCT alone (p=0.0020). Patients undergone to 
radiochemotherapy alone had a significantly higher local 
control than patients treated with IC (3-ys LC: 97% vs 40%: p= 
0.0014). The stage affect the final multivariate model for OS 
(p=0.03), and DFS (p=0.0021) and LC (p=0.0086). Acute 
toxicity was similar in both groups. 
Conclusions: Compared with the induction chemotherapy 
group, concurrent chemoradiotherapy alone could 
significantly improve prognosis in terms of overall survival, 
loco-regional failure-free survival, even if patients treated 
with neoadjuvant chemotherapy had a very locally advanced 
disease. However, distant metastatic events still remain a 
problem, and larger and multicenter randomized trials are 
required to assess whether IC followed by RTCT is superior to 
RTCT alone. 
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Purpose/Objective: Despite the numerous retrospective and 
prospective series about IMRT treatment of Nasopharyngeal 
Carcinoma (NPC) in the literature, there is not a clear 
consensus in dose schemes and target volume definitions. 
Furthermore, there are few studies about non-Asiatic 
populations, with small data on European countries. The aim 
of this study is to describe and analyze our results in treating 
all-stages NPC with IMRT-simultaneous integrated boost (SIB), 
in a non-endemic area.  
Materials and Methods: We performed a retrospective 
review of 52 consecutive patients with NPC treated with 
curative intention with IMRT-SIB in our institution between 
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2007 and 2013. Patients with incomplete data and without 
follow up before treatment, were excluded. All patients 
received the same RT scheme: 33 daily fractions of 1.64 Gy 
to intermediate-risk volume and 2.12 Gy to high-risk volume 
with SIB, reaching 54.12 Gy and 69.96 Gy respectively.  
Descriptive statistics (frequencies and percentages) were 
used to report the characteristics of patients, their clinical 
status, the treatment performed and toxicities reported. The 
oncologic outcomes were overall survival (OS), loco-regional 
relapse-free survival (LRRFS), metastases-free survival (MFS) 
and progression free survival (PFS). These variables were 
estimated using the Kaplan-Meier method (95% CI level). 
Results: The median follow-up was 28.1 months. Median age 
was 49 years (range, 15 - 78). There was a predominance of 
men (67.3%), white race (80.8%). The tumors were 
undifferentiated (WHO III) in 40 patients (76.9%), and EBV 
positive in 33 (63.5%). There was a majority of locally 
advanced disease, with 48 patients (92.3%) stage III-IV. Only 5 
patients (9.6%) were treated exclusively with RT, while the 
rest received chemotherapy (CT), mainly concurrent (84.6%). 
Neoadjuvant CT was delivered to 22 (42.3%) patients, 
adjuvant CT to 4 (7.7%) patients and 15 (28.8%) patients 
received neoadjuvant and adjuvant CT. The 1- and 3-year 
estimation of OS was 98.0% and 85.5%, respectively, while 1 
and 3-year LRRFS were 100% and 95.8%, respectively. 
Conclusions: The treatment of NPC (predominantly locally 
advanced) using IMRT-SIB in our institution, offers a rational 
and feasible alternative of treatment, comparable to results 
described so far in endemic population.  
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Purpose/Objective: To analyse the outcome of all the 
patients treated in our Institute for Nasopharyngeal 
Carcinoma without distant metastasis at diagnosis in a period 
of 14 years. 
Materials and Methods: From January 2000 to December 
2013 187 consecutive patients received radiotherapy +/- 
chemotherapy (neoadjuvant and/or concomitant). 
Results: According to TNM classification, UICC 2009, 31% of 
patients were in stage I-II, 69% in stage III-Iva-b. The 
predominant histologic pattern was WHO type 3 in 70.6% of 
patients. At 10 years Overall Survival (OS) has been 65+/-6%, 
Disease Specific Survival (DSS) 82+/-3%, Loco Regional Control 
(LRC) 73+/-5%, Distant Metastasis Free Survival (DMFS) 63+/-
5%. Many clinical variables (gender, histology, age, T and N 
classification, Stage, Karnofski index) and others related to 
treatment (chemotherapy, waiting time from histological 
diagnosis to first treatment, prolongation of overall radiation 
treatment time, technique of treatment - 3DCRT vs IMRT-, 
fractionation), have been analyzed.At univariate analysis OS 
was statistically related to T and N class, clinical stage, 
Karnofski index, concomitant chemotherapy, respect of 
overall treatment time, modality of irradiation. LRC was 
related to T class, clinical stage, chemotherapy, use of IMRT 
and fractionation (2.3 Gy/fr vs 2 Gy/fr). The DMFS resulted 
related to T class, clinical stage, chemotherapy and time 
between the start of neoadjuvant chemotherapy and 
radiotherapy. At multivariate analysis, the statistically 
significant factors at univariate analysis were considered. For 
OS the final model maintained T class, stage, age, and 
chemotherapy. LRC was related with stage, chemotherapy 
and the use of IMRT. DMFS resulted related to the time 
between start of neoadjuvant chemotherapy and the start of 
radiotherapy (worse results for length of time superior to 30 
days). 
Conclusions: In our single experience the introduction of 
IMRT, frequently associated with IGRT, has been associated 
with a sharp improvement of LRC at 5 yrs (88+/-4% with IMRT 
vs 64+/-7% with 3DCRT, p 0.010), even if we consider the 
association with chemotherapy in various modality 
(neoadjuvant chemo followed by RTT alone or RTT/chemo, 
exclusive radio-chemotherapy or radiotherapy alone). Other 
variables could be involved in this improvement, such as a 
better local definition with MR co-registration during 
planning in the last years, or a better staging with the 
frequent use of CT-PET which can identify cases with distant 
metastasis at first diagnosis. 
The gain obtained with IMRT was also evident in an 
improvement in OS (82+/-5% vs 70+/-5% at 5 yrs, p 0.038) 
while no differences were found in DMFS. The analysis is still 
in progress. 
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Purpose/Objective: To investigate the correlation between 
location of loco-regional failures and previous intensity-
modulated radiation therapy (IMRT) target volumes in 
patients with head and neck (H&N) cancer. 
Materials and Methods: 65 consecutive patients (44 men; 
mean age 59.8 years) presenting with biopsy proven failure 
between May 2011 and April 2014 were retrospectively 
reviewed. Primary tumour location was nasopharynx (n = 4), 
oropharynx (n = 23), oral cavity (n = 11), hypopharynx (n = 4), 
larynx (n = 15), salivary gland (n = 1), primary unknown (n= 
1), and sinus (n = 6). Forty-eight patients had primary and 17 
post-operative (chemo)IMRT. Primary radical doses of 65-
70Gy and 54-56 Gy (30-35 fractions) were delivered to high 
dose (PTV1) and prophylactic (PTV2) target volumes, 
respectively, using a SIB-IMRT technique. In the post-
operative setting the dose to PTV1 was 60-66 Gy (30-33 
fractions). The sites of loco-regional failure (persistent or 
recurrent disease) were delineated on the diagnostic FDG-
PET-CT or CT scans which were co-registered with RT 
